| 引用本文： |
-
刘静雨,石亮亮,朱礼胜,熊英,彭纲.TP vs.TP联合PD-1单抗方案治疗局部晚期鼻咽癌近期疗效及安全性研究[J].广西科学,2023,30(5):1009-1016. [点击复制]
- LIU Jingyu,SHI Liangliang,ZHU Lisheng,XIONG Ying,PENG Gang.Comparative Efficacy and Safety of TP,TP plus Anti-PD-1 Regimen in the Treatment of Locally Advanced Nasopharyngeal Carcinoma[J].Guangxi Sciences,2023,30(5):1009-1016. [点击复制]
|
|
| 摘要: |
| 为了比较接受紫杉醇+顺铂(Paclitaxel+Cisplatin，TP)、TP联合程序性死亡受体1(Programmed Death-ligand 1，PD-1)单抗方案序贯同步放化疗治疗局部晚期鼻咽癌的近期疗效及安全性，本研究回顾分析了2019年1月至2020年12月于华中科技大学同济医学院附属协和医院肿瘤中心诊治的108例局部晚期鼻咽癌患者的临床资料，并比较两组治疗方案的近期疗效与不良反应发生率。鼻咽癌患者接受诱导治疗和同步放化疗后，TP联合PD-1单抗组(n=43)客观缓解率(Object Response Rate，ORR)均略高于TP组(n=65)，但差异无统计学意义;同步放化疗后完全缓解(Complete Response，CR)率显著高于TP组,差异有统计学意义。TP联合PD-1单抗组白细胞减少、淋巴细胞减少和肺炎发生率高于TP组，差异有统计学意义。TP联合PD-1单抗治疗方案序贯同步放化疗治疗局部晚期鼻咽癌近期疗效略高于TP诱导化疗组，差异无统计学意义。TP联合PD-1单抗治疗组白细胞减少、淋巴细胞减少和肺炎发生率显著高于TP组，但处于安全可控的范围。 |
| 关键词: 局部晚期鼻咽癌 免疫检查点抑制剂 程序性死亡受体1 诱导化疗 临床疗效 安全性 |
| DOI：10.13656/j.cnki.gxkx.20231023.001 |
| 投稿时间：2022-04-30修订日期：2022-05-31 |
| 基金项目:国家自然科学基金项目(82071067)资助。 |
|
| Comparative Efficacy and Safety of TP,TP plus Anti-PD-1 Regimen in the Treatment of Locally Advanced Nasopharyngeal Carcinoma |
|
LIU Jingyu, SHI Liangliang, ZHU Lisheng, XIONG Ying, PENG Gang
|
| (Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China) |
| Abstract: |
| In order to compare the short-term efficacy and safety of TP (Paclitaxel+Cisplatin),TP plus anti-PD-1 for locally advanced nasopharyngeal carcinoma，from January 2019 to December 2020,the clinical data of 108 patients with locally advanced nasopharyngeal carcinoma in the Cancer Center of Wuhan Union Hospital,Tongji Medical College,Huazhong University of Science and Technology were collected for retrospective analysis.The short-term efficacy and incidence of adverse reactions were compared between the two groups of treatment.After induction chemotherapy and concurrent chemoradiotherapy,the Objective Response Rate (ORR) was slightly better in the TP plus anti-PD-1 regimen (n=43) than that in the TP regimen (n=65),but the difference was not statistically significant.After concurrent chemoradiotherapy,the Complete Response (CR) rate in the TP plus anti-PD-1 group was significantly higher than that in the TP group,and the difference was statistically significant.The incidence of leukopenia、lymphopenia and pneumonia was higher in the TP plus anti-PD-1 regimen than that in the TP regimen,and the difference was statistically significant.The short-term efficacy of TP plus anti-PD-1 group was slightly better than that in the TP group in locally advanced nasopharyngeal carcinoma,but the difference was not statistically significant.The incidence of leukopenia,lymphopenia and pneumonia in the TP plus anti-PD-1 regimen was significantly higher than that in the TP group,but it was in a safe and controllable range. |
| Key words: locally advanced nasopharyngeal carcinoma immune checkpoint inhibitor programmed cell death 1 receptor induction chemotherapy clinical efficacy safety profiles |
